Pasithea Therapeutics Corp. — Director's Dealing 2024

Mar 2, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2024-03-01

Reporting Person: Currie Graeme Martin (Chief Development Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-03-01	Stock Option (right to buy)	$8.34	A	5938	Acquired	2034-02-28	Common Stock (5938)	Direct

Footnotes

F1: The option award (the "Option") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The Option fully vested upon issuance and became exercisable on March 1, 2024.